<DOC>
	<DOCNO>NCT00318370</DOCNO>
	<brief_summary>The purpose study determine investigational drug call MORAb-003 useful use approved cancer drug treat woman ovarian cancer . MORAb-003 monoclonal antibody direct antigen ovarian cancer .</brief_summary>
	<brief_title>Effectiveness MORAb-003 Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy</brief_title>
	<detailed_description>MORAb-003 monoclonal antibody potential effective agent epithelial ovarian cancer ( include primary fallopian tube peritoneal adenocarcinoma ) either alone combination drug . MORAb-003 work different mechanism cancer therapeutic show well tolerate . This study allow opportunity determine MORAb-003 work either single agent 1. treat CA125-only relapse , 2. combination standard platinum taxane chemotherapy treat symptomatic relapse , 3. prolong second response chemotherapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Female subject least 18 year age , histologically confirm diagnosis nonmucinous epithelial ovarian cancer ( include fallopian tube primary peritoneal cancer ) first relapse first remission 6 18 month duration . Subjects must undergo surgery . Subjects must receive primary chemotherapy , include least one platinum agent . Subject eligible retreatment chemotherapy regimen use induce remission ( Exception : may reduce dose discontinue taxane contraindicate due neurotoxicity . ) CA125 must elevate prior original chemotherapy . CA125 must elevate time relapse . Life expectancy great equal 6 month , estimate investigator . Eastern Cooperative Oncology Group performance status 0 , 1 2 Subjects must consent use medically acceptable method contraception throughout study period 28 day final MORAb003 administration , unless surgically sterile . Any significant concomitant medical condition must well control stable opinion investigator least 30 day prior Study Day 1 . Laboratory clinical result within 2 week prior Study Day 1 follow : Absolute neutrophil count ( ANC ) ≥ 1.2 x 10e9/L Platelet count ≥ 100 x 10e9/L Hemoglobin ≥ 8 g/dL Subject must willing able provide write informed consent . Translations inform consent information may provide , subject local institutional review board 's ( IRB 's ) policy . Known central nervous system ( CNS ) tumor involvement . Evidence active malignancy require treatment . Clinically significant heart disease ( e.g. , congestive heart failure New York Heart Association Class III IV , angina well controlled medication , myocardial infarction within 6 month ) . Electrocardiogram ( ECG ) demonstrate clinically significant arrhythmia ( Exception : Subjects chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia [ SVT ] , eligible ) . Active serious systemic disease , include active bacterial fungal infection . Active hepatitis HIV infection . Treatment within three month immunomodulatory therapy ( e.g . interferon , immunoglobulin therapy , interleukin 1 receptor antagonist [ IL1RA ] systemic corticosteroid ) . Short term systemic corticosteroid topical intraarticular steroid acceptable , subject judgment investigator . Treatment monoclonal antibody therapy AND evidence immune allergic reaction document HAHA . Maintenance first remission taxane chemotherapeutic agent ( ) . Initiation plan initiation cancer therapy give induce primary remission . Substitutions agent materially similar use original regimen permissible . Breastfeeding , pregnant , likely become pregnant study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Primary Fallopian Tube Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
</DOC>